Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

This study has been terminated.
(Funding ceased)
Heart and Stroke Foundation of Ontario
LEO Pharma
Information provided by (Responsible Party):
Wendy Lim, St. Joseph's Healthcare Hamilton Identifier:
First received: September 13, 2005
Last updated: April 18, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2016
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)